Cargando…

KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer

Abiraterone, a novel androgen synthesis inhibitor, has been approved for castration-resistant prostate cancer (CRPC) treatment. However, most patients eventually acquire resistance to this agent, and the underlying mechanisms related to this resistance remain largely unelucidated. Lysine acetyltrans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Dingheng, Song, Yarong, Yu, Ying, Wang, Decai, Liu, Bing, Chen, Liang, Li, Xuexiang, Li, Yunxue, Cheng, Lulin, Lv, Fang, Zhang, Pu, Xing, Yifei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357915/ https://www.ncbi.nlm.nih.gov/pubmed/34381019 http://dx.doi.org/10.1038/s41419-021-04077-w

Ejemplares similares

CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells
por: Yu, Ying, et al.
Publicado: (2022)

ATF4/CEMIP/PKCα promotes anoikis resistance by enhancing protective autophagy in prostate cancer cells
por: Yu, Ying, et al.
Publicado: (2022)

CEMIP promotes extracellular matrix‐detached prostate cancer cell survival by inhibiting ferroptosis
por: Liu, Bing, et al.
Publicado: (2022)

Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism
por: Chen, Liang, et al.
Publicado: (2022)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
por: Simon, Iris, et al.
Publicado: (2021)

SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4
por: Cheng, Lulin, et al.
Publicado: (2023)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

Ligand induced dissociation of the AR homodimer precedes AR monomer translocation to the nucleus
por: Shizu, Ryota, et al.
Publicado: (2019)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
por: James, Aloysius, et al.
Publicado: (2018)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer
por: Boerrigter, Emmy, et al.
Publicado: (2021)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics
por: Deris, Atefeh, et al.
Publicado: (2023)

Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer
por: Torquato, Samantha, et al.
Publicado: (2019)

Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
por: Omlin, A, et al.
Publicado: (2013)

Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer
por: Sundar, Santhanam, et al.
Publicado: (2015)

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
por: Poon, Darren M. C., et al.
Publicado: (2016)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: El-Amm, Joelle, et al.
Publicado: (2017)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
por: Rauch, Simon, et al.
Publicado: (2016)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Remarkable response to abiraterone acetate in castration‐resistant prostate cancer patient with aggressive liver metastasis
por: Katsui, Masahiro, et al.
Publicado: (2018)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
por: Parikh, Mamta, et al.
Publicado: (2021)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
por: Demirci, Ayşe, et al.
Publicado: (2021)

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2022)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
por: Liu, Yang, et al.
Publicado: (2021)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
por: Liu, Min, et al.
Publicado: (2023)

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
por: Sicotte, Hugues, et al.
Publicado: (2022)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
por: Tseng, Chi-Shin, et al.
Publicado: (2023)

Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification
por: Lyu, Fang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kev2qrq9hd0iqpdr1rl7imsuac